Another great theory and I hope we have a partner or one in

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps Respert24 #119067
652
Another great theory and I hope we have a partner or one in the works. I just can’t let myself get that excited about a possible partnership. I just won’t have that type of let down swirling around in my head again. For one… the rules of Pharma has been we will partner with you when you show me an approval of your drug little biotech. We have been real close but the proverbial winning cigar… we are not smoking it just yet. I believe we will. It’s not if we will… its when we will…in my opinion.

Big Pharma across the board has literally spent a combined crazy amount in the billions of dollars on drugs they could NOT get approved even though they had great phase 2 results. They have been stung numerous times on great results that didn’t pan out. They decided a few years back not to use the fire sale approach and just to wait for the real approval first and buy the biotech out before marketing the drug. Bet on the sure thing. Makes sense for them.

Our management has speculated about BTD’s being enough to be bought out. Maybe 2 BTD’s with huge results could make that happen. It’s not an approval yet but a wise gambling CEO of a big Pharma might bite? Maybe… it’s a stretch and doesn’t fit the past formulas as a norm. But maybe?

I don’t want to keep raining on the parade about a possible buy out or partnership. The truth is we have nothing solid to go on either direction. Be careful what you lead yourself to believe is all I am saying. Don’t get yourself into one of those major blow back situations if what you want to believe isn’t actually happening or going to happen.

Just remember either way partnership or not we have a golden egg in our pocket with great potential and we may still get 2 or 3 possible approvals this year with or without a partner. Remember… it’s not if we have a good platform drug anymore. It’s when we start crossing the finish lines. Let’s hope whomever we hire as a new CEO that this is not their first rodeo. That they have been here and more.

It may sound like I am down on Leronlimab. I am not. I am super hopeful and very optimistic about our future. I believe in the science and what we have learned about this drug from the trials we have had so far. I am not giving investment advice to anyone. Do what’s comfortable for you. I know how comfortable I am. Have I said it’s all rainbows and (yellow butterflies/TechGuru) butterflies before… that’s what I am hoping the next sign is… news will definitely come when we have material events.

Having great news when we need it… material events baby!!! This much we know is mandatory. I don’t mind the wait… I don’t flip and never have. I don’t short and never will. I am here for the long run and always have been. To be long and strong. So what if we speculate and dream a little here and there. If your still here now… you have the bug that is…CYDY. I will wait until the end… keep waiting… it’s coming… it’s not if… it’s when. It’s what I keep telling myself and it sure the hell helps me. I hope it helps you too… it’s just a matter of time in my hopes and dreams.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FDA Greenlights VELO: A Turning Point for Reynolds?

Updated Category News Views 33

FDA Decision: A Big Win for Reynolds American Boy, am I seeing a shift in the winds. The FDA's green light for VELO nicotine pouches adds a fresh feather to Reynolds American's cap. In a gritty industry like tobacco, getting FDA's nod ain't just about safety; it’s a strategic leg up against traditional smoke. My gut tells me this isn't just about keeping pace. It's...

Continue Reading
Tampa General Elevates Lokenauth to CFO Amid Growth

Updated Category News Views 36

Charting New Waters at Tampa General Out here in the blue, the tides of healthcare can swell mighty quick. That's where Tampa General Hospital keeps its anchor firm, announcing Lijah Lokenauth's leap to Executive VP and CFO. If you ask me, it's all about keeping the ship steady—this fella's been steering their financial boat through some hefty waves since 2018....

Continue Reading
Anguilla Culinary Festival 2027: A Feast Beyond Food

Updated Category News Views 101

A Culinary Quest in the Caribbean Imagine this: a culinary pilgrimage where the Caribbean’s essence is served on a plate. The Anguilla Culinary Experience (ACE), set for April 28 through May 2, 2027, isn't just about stretching waistbands. It’s about embracing the spirit and flavors of Anguilla, one of the world's cherished culinary hotspots. Cooking with Purpose ACE...

Continue Reading
Cboe's Third Quarter Packs a Punch with Strong Gains

Updated Category News Views 62

Making Waves in the Market There's no sugar-coating it—Cboe Global Markets has had a hell of a third quarter in 2026. With their diluted EPS climbing to a record $4.08, a 43% jump from last year, it's no surprise their stock ticker, CBOE, is catching some eyes. Adjusted diluted EPS also made a splash, soaring 36% to $3.63 compared to 2025 figures. Their strategic moves...

Continue Reading
Sunset World Group: 32 Years of Beachside Legacy

Updated Category News Views 18

Celebrating a Beachside Milestone Out there in the sun-soaked corners of Cancun, it's another sunburnt milestone for the folks over at Sunset Royal Beach Resort. We're talking a full 32 years of greeting guests with their signature tropical flair. Now that's the kind of longevity you just don't find in today's fleeting hospitality market. A pat on the back to any...

Continue Reading
Runners Hit NYC Streets to Spotlight Liver Disease

Updated Category News Views 9

From the Heart: Marathon Runners Champion Liver Disease Awareness There’s something raw and powerful about a community uniting to raise awareness for a cause that's touched so many lives. This Sunday, the TCS New York City Marathon becomes more than a race—it transforms into a moving tapestry of human stories, as runners take to the streets to spotlight liver disease...

Continue Reading
Buyers Edge Appoints Sam Peterson as CTO to Lead AI Shift

Updated Category News Views 68

Anticipating a New Era of AI with Buyers Edge The rumble through the procurement world was more of a jolt this week as Buyers Edge Platform (BEP) threw a new player into the tech gauntlet. Sam Peterson has been handed the reins as the Chief Technology Officer. The goal? To supercharge BEP's innovation engine with some AI-driven gusto. What's in the Cards for Buyers Edge...

Continue Reading
MediaGo Wins Big in France with Optimized Strategies

Updated Category News Views 55

MediaGo's Winning Edge in Advertising Shake the dust off your boots and get ready for a tale of triumph straight out of San Francisco. MediaGo, the top dog in global intelligent advertising platforms, just added a couple of shiny awards to its trophy case thanks to the prestigious Les Cas d'OR 2026 in France. And let me tell ya, these wins aren't just about some pretty...

Continue Reading
Huawei's New O&M Strategies: A Game-Changer?

Updated Category News Views 42

Huawei's Latest O&M Revolution: What's on the Table? With Huawei dropping fresh O&M solutions at HUAWEI CONNECT 2026 in Shanghai, they're not just shaking things up—they're kicking the whole operation management game into hyperdrive using AI. They're zeroing in on the whole digital twin strategy, boasting some nifty pre-event, in-process, and post-event capabilities to...

Continue Reading
Standards Touch 2027 Student Paper Competition

Updated Category News Views 37

Diving into Trust: ANSI's 2027 Paper Challenge Out from the buzz of New York, the American National Standards Institute (ANSI) has stirred up some real brain-teasing talk for students across the country. Kicking off the 2027 Student Paper Competition, they're handing students a chance to ponder a question we take for granted every day. Do we ever truly consider what makes...

Continue Reading

Top 5 Most Recently Viewed Articles

H.C. Wainwright Adjusts Target for Inventiva Amid Changes

Updated Category News Views 78

Understanding H.C. Wainwright's Updated Price Target for Inventiva Recently, H.C. Wainwright made notable adjustments to its price target for Inventiva SA (NASDAQ: IVA), lowering it to $13.00 from the previous $14.00 while continuing to maintain a Buy rating. This decision came closely after Inventiva announced an important financing deal, which is crucial for the...

Continue Reading
Zymeworks Unveils Innovative Cancer Therapies at AACR Meeting

Updated Category News Views 226

Breakthrough Cancer Therapies: Zymeworks Announcements Zymeworks Inc., a leading name in biotechnology, is making headlines with the introduction of cutting-edge treatments aimed at tackling some of the most formidable health challenges. With a commitment to enhancing therapeutic options for cancer and other diseases, Zymeworks is developing multifunctional...

Continue Reading
Ontrak Health and Sentara Team Up for Enhanced Care Solutions

Updated Category News Views 30

Ontrak Health Expands Behavioral Health Collaboration Ontrak, Inc. (NASDAQ: OTRK), an innovative leader in AI-powered behavioral healthcare, is excited to share details of its expanded partnership with Sentara Health Plans. This significant move is set to enhance services in the behavioral health domain, promising improved outcomes for a wide range of members. Expanding...

Continue Reading
Gigasoft's ProEssentials v10 Targets AI Need for Accurate Coding

Updated Category News Views 340

AI Code Hallucinations: A Real Developer Nightmare Cracking the code is one thing, but developers sure aren’t laughing when they have to deal with hallucinations from their AI tools. You know the drill: you ask your shiny AI assistant for charting code and, voila, you're confronted with property names that don’t exist. Cue the frustration, the documentation digging,...

Continue Reading
Exploring Middlefield Canadian Income PCC's Asset Value Insights

Updated Category News Views 88

Understanding Middlefield Canadian Income PCC's Net Asset Value Middlefield Canadian Income PCC is a protected cell company that plays a significant role in asset management. It's important for investors to keep an eye on the company's financial metrics, particularly the Net Asset Value (NAV), as it serves as a key indicator of the company's financial health and...

Continue Reading